Ménétrier's disease: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
{{SI}}
{{SI}}
{{CMG}};{{AE}}{{Akshun}}
{{CMG}};{{AE}}{{Akshun}}
{{SK}}
{{SK}}


Line 175: Line 176:
Common symptoms of Ménétrier's disease include epigastric pain after meals, dyspepsia, nausea and vomiting, anorexia, weight loss, and edema.
Common symptoms of Ménétrier's disease include epigastric pain after meals, dyspepsia, nausea and vomiting, anorexia, weight loss, and edema.


===Prognosis===
==Prognosis==
Ménétrier's disease usually lasts for 2-14 weeks, with complete resolution being the rule.
In children, Ménétrier's disease usually lasts for 2-14 weeks, with complete resolution being the rule.


==Physical Examination==
==Physical Examination==
Line 184: Line 185:
Laboratory findings consistent with the suggestive of Ménétrier's disease include hypoalbuminemia and hypochlorhydria resulting from protein-losing enteropathy and decreased acid secretion respectively.
Laboratory findings consistent with the suggestive of Ménétrier's disease include hypoalbuminemia and hypochlorhydria resulting from protein-losing enteropathy and decreased acid secretion respectively.


===Electrocardiogram===
==X-ray==
There are no ECG findings associated with Ménétrier's disease.
A barium meal may be helpful in the diagnosis of Ménétrier's disease. Findings on an upper GI series suggestive of Ménétrier's disease include thickened and lobulated gastric folds located in
 
===X-ray===
A barium swallow be helpful in the diagnosis of Ménétrier's disease. Findings on an upper GI series suggestive of Ménétrier's disease include thickened and lobulated gastric folds located in
gastric fundus and body.
gastric fundus and body.


===Echocardiography or Ultrasound===
==CT scan==
There are no echocardiography/ultrasound findings associated with Ménétrier's disease.
 
===CT scan===
Abdominal CT scan may be helpful in the diagnosis of Ménétrier's disease. Findings on CT scan suggestive of Ménétrier's disease include massive lobulated gastric folds. An important feature of Ménétrier's disease which differentiates it from gastric carcinoma includes the presence of pliable gastric folds as compared to rigid and aperistaltic gastric folds seen in carcinoma.
Abdominal CT scan may be helpful in the diagnosis of Ménétrier's disease. Findings on CT scan suggestive of Ménétrier's disease include massive lobulated gastric folds. An important feature of Ménétrier's disease which differentiates it from gastric carcinoma includes the presence of pliable gastric folds as compared to rigid and aperistaltic gastric folds seen in carcinoma.


===MRI===
==Other Imaging Findings==
There are no MRI findings associated with Ménétrier's disease.
 
===Other Imaging Findings===
Endoscopy may be helpful in the diagnosis of Ménétrier's disease. Findings on an endoscopy suggestive of Ménétrier's disease include enlarged, nodular and coarse gastric folds.
Endoscopy may be helpful in the diagnosis of Ménétrier's disease. Findings on an endoscopy suggestive of Ménétrier's disease include enlarged, nodular and coarse gastric folds.


===Other Diagnostic Studies===
==Medical Therapy==
There are no other diagnostic studies associated with Ménétrier's disease.
 
===Medical Therapy===
Tthe mainstay of therapy for Ménétrier's disease is supportive care with intravenous albumin (if symptomatic) and parenteral nutritional supplementation. However, some benefit has also been observed with the use of anticholinergic drugs, acid suppression, octreotide and H. pylori eradication.
Tthe mainstay of therapy for Ménétrier's disease is supportive care with intravenous albumin (if symptomatic) and parenteral nutritional supplementation. However, some benefit has also been observed with the use of anticholinergic drugs, acid suppression, octreotide and H. pylori eradication.



Revision as of 17:47, 17 January 2018

WikiDoc Resources for Ménétrier's disease

Articles

Most recent articles on Ménétrier's disease

Most cited articles on Ménétrier's disease

Review articles on Ménétrier's disease

Articles on Ménétrier's disease in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ménétrier's disease

Images of Ménétrier's disease

Photos of Ménétrier's disease

Podcasts & MP3s on Ménétrier's disease

Videos on Ménétrier's disease

Evidence Based Medicine

Cochrane Collaboration on Ménétrier's disease

Bandolier on Ménétrier's disease

TRIP on Ménétrier's disease

Clinical Trials

Ongoing Trials on Ménétrier's disease at Clinical Trials.gov

Trial results on Ménétrier's disease

Clinical Trials on Ménétrier's disease at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ménétrier's disease

NICE Guidance on Ménétrier's disease

NHS PRODIGY Guidance

FDA on Ménétrier's disease

CDC on Ménétrier's disease

Books

Books on Ménétrier's disease

News

Ménétrier's disease in the news

Be alerted to news on Ménétrier's disease

News trends on Ménétrier's disease

Commentary

Blogs on Ménétrier's disease

Definitions

Definitions of Ménétrier's disease

Patient Resources / Community

Patient resources on Ménétrier's disease

Discussion groups on Ménétrier's disease

Patient Handouts on Ménétrier's disease

Directions to Hospitals Treating Ménétrier's disease

Risk calculators and risk factors for Ménétrier's disease

Healthcare Provider Resources

Symptoms of Ménétrier's disease

Causes & Risk Factors for Ménétrier's disease

Diagnostic studies for Ménétrier's disease

Treatment of Ménétrier's disease

Continuing Medical Education (CME)

CME Programs on Ménétrier's disease

International

Ménétrier's disease en Espanol

Ménétrier's disease en Francais

Business

Ménétrier's disease in the Marketplace

Patents on Ménétrier's disease

Experimental / Informatics

List of terms related to Ménétrier's disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Synonyms and keywords:

Overview

Ménétrier's disease (also known as hyperplastic hypersecretory gastropathy and giant hypertrophic gastropathy and named after a French physician Pierre Eugène Ménétrier, 1859-1935), is a disorder in which the gastric mucosal folds (rugae) are enlarged[1] (and the total weight of the stomach is increased), making the surface of the stomach look a bit like the brain gyri. The altered gastric mucosa secretes massive amounts of mucus, resulting in low plasma protein levels. The tissue may be inflamed and may contain ulcers. The disease also causes glands in the stomach to waste away and causes the body to lose fluid containing a protein called albumin.

There are two forms of the disease: a childhood form and an adult form. The childhood form has a better prognosis. It affects boys and girls equally, most often after they have a viral illness caused by cytomegalovirus (CMV) or a bacterial infection caused by Helicobacter pylori. Children are not born with this disease, and it is not passed from parents to their children.[2]. The adult form linked with overexpression of transforming growth factor alpha (TGF-α). The adult variety is four times more common in men, primarily affecting men between ages 30 and 60.

The presenting symptoms are

Ménétrier's disease increases a person's risk of stomach cancer.[3]

Microscopically, the disease is characterized by hyperplasia of the crypts, which are elongated and may appear cystic or corkscrew-like. Since it predisposes to stomach cancer, periodic endoscopic surveillance is mandated. CMV-related Ménétrier is often self-limited.

The disease must be diagnosed by x-ray (rare) or endoscopy and biopsy of the stomach. In adults, treatment may include medications to relieve ulcer symptoms and treat inflammation, and a high-protein diet. Part or all of the stomach may need to be removed if the disease is severe. Pediatric cases are normally treated for symptoms with the disease clearing up in weeks to months.

Other forms of hyperplastic gastropathy include Zollinger-Ellison syndrome.

Overview

Ménétrier's disease is a rare, idiopathic, premalignant disease of the mucous glands of the stomach characterized by massive gastric folds. The most commonly involved location is the fundus and corpus of the stomach. Ménétrier's disease is also known as cystic gastritis, giant hypertrophic gastritis, giant mucosal hypertrophy and hyperplastic gastropathy.

Historical Perspective

In 1888, Pierre Ménétrier, a French pathologist coined the term Ménétrier's disease after describing mucosal hypertrophy involving part or all of the stomach.

Classification

There is no established system for the classification of Ménétrier's disease.

Pathophysiology

The exact pathogenesis of Ménétrier's disease is not fully understood. However, it is thought that Ménétrier's disease is often due to excessive secretion of transforming growth factor alpha (TGF-α).(PMID 18321437) seen especially in infections such as CMV, H.pylori and herpes simplex.

  • Overproduction of transforming growth factor-α leads to increased signaling of the epidermal growth factor receptor (EGFR), a transmembrane receptor with tyrosine kinase activity.
  • Upon activation, the EGFR activates a series of intracellular signaling pathways that leads to increased cell proliferation.
  • Excessive secretion of TGF-α may lead to selective expansion of gastric foveolar cell (surface mucous cell hyperplasia) with edema, and variable degrees of inflammation.
  • Hyperplasia of gastric foveolar cells leads to enlarged gastric folds with gastric pits being elongated and tortuous. In addition, there is also excessive mucus production.
  • Other gastric glands such as chief or parietal cells are replaced by mucus-secreting cells leading to decreased effective gastric acid production.
  • In Ménétrier's disease, there is widening of gap junctions and tight junctions between cells as compared to healthy subjects, and it is believed that proteins traverse from the gastric mucosa into the gastric lumen through these widened spaces. Hence, an increase in intracellular permeability results in protein-losing enteropathy.
  • In a nutshell, mucosal hyperplasia with decreased number of chief and parietal cells leads to excessive mucus production, protein loss from the stomach and subsequent hypochlorhydria or achlorhydria. However, it may be noted that Ménétrier's disease is typically but not always associated with protein-losing gastropathy and hypochlorhydria.

Genetics

  • Genes involved in the pathogenesis of Ménétrier's disease include mutation in SMAD4 gene (associated with juvenile polyposis. Mutation in SMAD4 gene may lead to a mixed hypertrophic/polypoid gastropathy. A recent study showed that a dominant 1244_1247delACAG mutation of SMAD4 was identified in each of the subjects with juvenile polyposis and in Ménétrier's disease. (PMID 27375208)
  • Overproduction of TGF-α leads to overactivation of EGF which may lead to hyperplasia of surface mucous cells.
  • Some researchers suggest a unifying hypothesis which suggest TGF-β–SMAD4 pathway inactivation and TGF-α overexpression related to Hp infection ultimately leads to Ménétrier's disease (PMID 22748914).

Associated conditions

  • H.pylori infection
  • CMV gastritis
  • HIV
  • Gastric cancer
  • Pulmonary infections
  • Thrombotic conditions

Gross pathology

  • Polypoid and hypertrophic gastric folds
  • Large cobblestone or cerebriform gastric folds
  • Mucosa have swollen, spongy appearance subdivided by creases
  • In rare cases, Ménétrier's disease may have hyperplastic gastric polyps

Microscopic pathology

  • Decreased parietal and chief cells
  • Intraepithelial lymphocytosis
  • Glandular tortuosity and dilation
  • Marked reduction in parietal cell number with replacement by mucous glands

Causes

Ménétrier's disease may be caused by over expression of transforming growth factor alpha (TGF-α)(PMID 18321437) seen especially with infections such as CMV, H.pylori and herpes simplex.

Differentiating Ménétrier's disease from Other Diseases

Ménétrier's disease must be differentiated from other conditions that presents with enlarged gastric folds such as Zollinger Ellison syndrome, inflammatory gastritis, granulomatous gastritis, gastric adenomas (lymphoma/carcinoma), and hereditary conditions (such as Familial Adenomatous Polyposis).

Disease Age of onset Risk factors Gastric area involved Type of gastric glands involved Inflammatory cells Symptoms Progression to malignancy
Nausea Vomitting Abdominal pain Other features
Menetrier's Disease 40-60s H.pylori infection

CMV gastritis

Body & fundus Mucosal cells Lymphocytes + + + Peripheral edema +
Zollinger Ellison syndrome 50s MEN 1 syndrome Fundus Parietal and mucosal cells Neutrophils + + + Recurrent ulcers -
Inflammatory & hyperplastic polyps 50s Gastritis and H.pylori Antrum Mucosal cells Neutrophils and lymphocytes + + + Rectal bleeding with diarrhea or constipation +/-
Granulomatous gastritis Variable History of prior surgery Body Mucosal cells Neutrophils and lymphocytes + + + Gastric outlet obstruction -
Familial adenomatous polyposis 50s Mutation in APC gene Body & fundus Parietal cells None - - - Asymptomatic to bleeding per rectum +
Adenomas (gastric) 60s Chronic gastritis and intestinal metaplasia Antrum Dysplastic cells Variable + + + Early satiety +

Epidemiology and Demographics

Ménétrier's disease is seen in both children and adults. In children Ménétrier's disease affects boys and girls equally. In adults, Ménétrier's disease is more commonly seen in the age group of 30 to 50 years with men are more commonly affected than females.

Risk Factors

Common risk factors in the development of Ménétrier's disease includes overstimulation of gastric mucosa by pituitary, hypothalamic, or vagal stimuli.

Diagnosis

  • There is no established criteria for the diagnosis of Ménétrier's disease. However, an endoscopic biopsy, chromium-labeled albumin test (GI protein loss), and 24-hour pH monitoring can establish the diagnosis of Ménétrier's disease. Endoscopy shows the typical gastric mucosal changes and biopsy establishes the histopathological variant of Ménétrier's disease. Biopsy is also done to rule out gastric carcinoma or lymphoma.
  • The most accurate method to diagnose Ménétrier's disease includes testing such as oesophagogastroduodenoscopy with gastric pH, serum albumin and full-thickness mucosal biopsy of the involved gastric mucosa.

History and Symptoms

Common symptoms of Ménétrier's disease include epigastric pain after meals, dyspepsia, nausea and vomiting, anorexia, weight loss, and edema.

Prognosis

In children, Ménétrier's disease usually lasts for 2-14 weeks, with complete resolution being the rule.

Physical Examination

Patients with Ménétrier's disease usually appear fatigued. Common physical examination findings of patients with Ménétrier's disease includes abdominal tenderness, peripheral edema and with signs of iron deficiency anemia such as pallor and brittle nails.

Laboratory Findings

Laboratory findings consistent with the suggestive of Ménétrier's disease include hypoalbuminemia and hypochlorhydria resulting from protein-losing enteropathy and decreased acid secretion respectively.

X-ray

A barium meal may be helpful in the diagnosis of Ménétrier's disease. Findings on an upper GI series suggestive of Ménétrier's disease include thickened and lobulated gastric folds located in gastric fundus and body.

CT scan

Abdominal CT scan may be helpful in the diagnosis of Ménétrier's disease. Findings on CT scan suggestive of Ménétrier's disease include massive lobulated gastric folds. An important feature of Ménétrier's disease which differentiates it from gastric carcinoma includes the presence of pliable gastric folds as compared to rigid and aperistaltic gastric folds seen in carcinoma.

Other Imaging Findings

Endoscopy may be helpful in the diagnosis of Ménétrier's disease. Findings on an endoscopy suggestive of Ménétrier's disease include enlarged, nodular and coarse gastric folds.

Medical Therapy

Tthe mainstay of therapy for Ménétrier's disease is supportive care with intravenous albumin (if symptomatic) and parenteral nutritional supplementation. However, some benefit has also been observed with the use of anticholinergic drugs, acid suppression, octreotide and H. pylori eradication.

Surgery

Surgery is not the first-line treatment option for patients with Ménétrier's disease. Surgery (subtotal/total gastrectomy) is usually reserved for patients with either massive protein loss unresponsive to medical therapy or with dysplasia or carcinoma.

References

Additional Resources

  • Rubin's Pathology, Clinicopathological Foundations of Medicine, 4th edition, Rubin, Gorstein, Rubin, Schwarting, Strayer. Lippincott Williams & Wilkins. ISBN 0-7817-4733-3

Template:SIB

de:Ménétrier-Syndrom

Template:WH Template:WS